Obchod NGM Biopharmaceuticals, Inc. - NGM CFD
Pridať medzi obľúbené- Zhrnutie
- Historické dáta
- Udalosti
- Výkaz ziskov a strát
- Súvahový list
- Peňažný tok
- Vlastníctvo
Podmienky obchodovania
| Rozpätie | 0.06 | ||||||||
|
Nočný poplatok dlhej pozície
Long position overnight fee
Prejsť na platformu | -0.030779% | ||||||||
|
Nočný poplatok krátkej pozície
Short position overnight fee
Prejsť na platformu | -0.013666% | ||||||||
| Nočný poplatok | 22:00 (UTC) | ||||||||
| Minimálne množstvo na obchodovanie | 1 | ||||||||
| Mena | USD | ||||||||
| Marža | 20% | ||||||||
| Burza cenných papierov | United States of America | ||||||||
| Provízia pri predaji | 0% |
*Information provided by Capital.com
Kľúčové štatistiky
| Predchádzajúce Zavrieť* | 12.88 |
| Otvoriť* | 12.68 |
| 1-ročná zmena* | -1.32% |
| Denný rozsah* | 12.39 - 12.86 |
| Rozsah 52 týždňov | 2.92-18.25 |
| Priemerný objem (10 dní) | 342.53K |
| Priemerný objem (3 mesiace) | 8.26M |
| Trhová kapitalizácia | 439.69M |
| Pomer P/E | -100.00K |
| Zdieľa mimoriadne | 81.73M |
| Výnosy | 58.11M |
| EPS | -1.94 |
| Dividenda (udalosť %) | N/A |
| Beta | 1.22 |
| Ďalší dátum zárobku | Feb 27, 2023 |
Všetky údaje poskytuje spoločnosť Refinitiv, okrem údajov označených hviezdičkou, čo sú *údaje poskytnuté Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Zatvorenie | Change | Change (%) | Otvorenie | High | Low |
|---|---|---|---|---|---|---|
| Jun 29, 2022 | 12.80 | 0.07 | 0.55% | 12.73 | 12.91 | 12.32 |
| Jun 28, 2022 | 12.88 | -1.09 | -7.80% | 13.97 | 14.24 | 12.50 |
| Jun 27, 2022 | 14.68 | 0.38 | 2.66% | 14.30 | 14.85 | 14.13 |
| Jun 24, 2022 | 14.64 | 1.16 | 8.61% | 13.48 | 14.73 | 13.48 |
| Jun 23, 2022 | 14.06 | 0.53 | 3.92% | 13.53 | 14.06 | 13.52 |
| Jun 22, 2022 | 13.75 | 0.28 | 2.08% | 13.47 | 14.18 | 13.47 |
| Jun 21, 2022 | 13.78 | 0.25 | 1.85% | 13.53 | 14.19 | 13.53 |
| Jun 17, 2022 | 13.58 | 0.69 | 5.35% | 12.89 | 13.95 | 12.87 |
| Jun 16, 2022 | 12.86 | 0.30 | 2.39% | 12.56 | 13.07 | 12.34 |
| Jun 15, 2022 | 12.97 | 0.46 | 3.68% | 12.51 | 13.10 | 12.34 |
| Jun 14, 2022 | 12.51 | 0.01 | 0.08% | 12.50 | 12.66 | 12.17 |
| Jun 13, 2022 | 12.31 | 0.02 | 0.16% | 12.29 | 12.92 | 12.08 |
| Jun 10, 2022 | 12.85 | 0.31 | 2.47% | 12.54 | 12.98 | 12.35 |
| Jun 9, 2022 | 12.82 | -0.48 | -3.61% | 13.30 | 13.78 | 12.43 |
| Jun 8, 2022 | 13.74 | -0.14 | -1.01% | 13.88 | 14.80 | 13.47 |
| Jun 7, 2022 | 14.03 | 0.15 | 1.08% | 13.88 | 14.86 | 13.63 |
| Jun 6, 2022 | 13.78 | -0.55 | -3.84% | 14.33 | 14.66 | 13.55 |
| Jun 3, 2022 | 14.49 | 0.91 | 6.70% | 13.58 | 14.78 | 13.45 |
| Jun 2, 2022 | 13.57 | 0.77 | 6.02% | 12.80 | 13.59 | 12.50 |
| Jun 1, 2022 | 12.99 | -0.90 | -6.48% | 13.89 | 14.06 | 12.99 |
NGM Biopharmaceuticals, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Výročný
- Štvrťročne
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Celkové príjmy | 85.589 | 77.141 | 108.665 | 103.544 | 87.368 | 77.882 |
| Výnosy | 85.589 | 77.141 | 108.665 | 103.544 | 87.368 | 77.882 |
| Celkové prevádzkové náklady | 93.95 | 94.566 | 112.979 | 152.884 | 191.201 | 198.577 |
| Predaj/Všeobecné/Správca. Náklady, Celkom | 11.845 | 14.83 | 17.265 | 23.631 | 27.229 | 36.865 |
| Výskum a vývoj | 82.105 | 79.736 | 95.714 | 129.253 | 163.972 | 161.712 |
| Prevádzkový príjem | -8.361 | -17.425 | -4.314 | -49.34 | -103.833 | -120.695 |
| Úrokový príjem (výdavky), čistý neprevádzkový | 1.806 | 2.358 | 3.622 | 6.692 | 1.939 | 0.42 |
| Iné, Net | 0.133 | -0.152 | 0.199 | -0.147 | -0.593 | -0.06 |
| Čistý príjem pred zdanením | -6.422 | -15.219 | -0.493 | -42.795 | -102.487 | -120.335 |
| Čistý príjem po zdanení | -6.922 | -14.159 | -0.493 | -42.795 | -102.487 | -120.335 |
| Čistý príjem pred extra. Položky | -6.922 | -14.159 | -0.493 | -42.795 | -102.487 | -120.335 |
| Čistý príjem | -6.922 | -14.159 | -0.493 | -42.795 | -102.487 | -120.335 |
| Príjem k dispozícii bežnému Extra. Položky | -6.922 | -14.159 | -0.493 | -42.795 | -102.487 | -120.335 |
| Príjem k dispozícii bežnému vr. Extra. Položky | -6.922 | -14.159 | -0.493 | -42.795 | -102.487 | -120.335 |
| Zriedený čistý príjem | -6.922 | -14.159 | -0.493 | -42.795 | -102.487 | -120.335 |
| Zriedený vážený priemer akcií | 64.9937 | 64.9937 | 64.9937 | 50.2975 | 68.4754 | 77.0854 |
| Zriedený EPS s výnimkou mimoriadnych položiek | -0.1065 | -0.21785 | -0.00759 | -0.85084 | -1.4967 | -1.56106 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | ||
| Zriedený normalizovaný EPS | -0.1065 | -0.21785 | -0.00759 | -0.85084 | -1.4967 | -1.56106 |
| Celkom mimoriadne položky | 0 | 0 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Celkové príjmy | 21.575 | 16.773 | 18.575 | 20.959 | 20.948 |
| Výnosy | 21.575 | 16.773 | 18.575 | 20.959 | 20.948 |
| Celkové prevádzkové náklady | 49.42 | 53.393 | 47.581 | 48.183 | 53.529 |
| Predaj/Všeobecné/Správca. Náklady, Celkom | 8.721 | 9.823 | 8.867 | 9.454 | 10.723 |
| Výskum a vývoj | 40.699 | 43.57 | 38.714 | 38.729 | 42.806 |
| Prevádzkový príjem | -27.845 | -36.62 | -29.006 | -27.224 | -32.581 |
| Úrokový príjem (výdavky), čistý neprevádzkový | 0.114 | 0.115 | 0.106 | 0.085 | 0.176 |
| Iné, Net | 0.187 | -0.187 | 0.035 | -0.095 | -0.045 |
| Čistý príjem pred zdanením | -27.544 | -36.692 | -28.865 | -27.234 | -32.45 |
| Čistý príjem po zdanení | -27.544 | -36.692 | -28.865 | -27.234 | -32.45 |
| Čistý príjem pred extra. Položky | -27.544 | -36.692 | -28.865 | -27.234 | -32.45 |
| Čistý príjem | -27.544 | -36.692 | -28.865 | -27.234 | -32.45 |
| Príjem k dispozícii bežnému Extra. Položky | -27.544 | -36.692 | -28.865 | -27.234 | -32.45 |
| Príjem k dispozícii bežnému vr. Extra. Položky | -27.544 | -36.692 | -28.865 | -27.234 | -32.45 |
| Zriedený čistý príjem | -27.544 | -36.692 | -28.865 | -27.234 | -32.45 |
| Zriedený vážený priemer akcií | 76.0341 | 77.0964 | 77.4089 | 77.7871 | 78.023 |
| Zriedený EPS s výnimkou mimoriadnych položiek | -0.36226 | -0.47592 | -0.37289 | -0.35011 | -0.4159 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Zriedený normalizovaný EPS | -0.36226 | -0.47592 | -0.37289 | -0.35011 | -0.4159 |
- Výročný
- Štvrťročne
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Celkové aktíva | 234.681 | 175.533 | 214.557 | 355.248 | 308.426 | 379.28 |
| Hotovosť a krátkodobé investície | 230.192 | 173.685 | 206.633 | 344.511 | 295.156 | 366.253 |
| Hotovosť a ekvivalenty | 45.463 | 25.593 | 56.923 | 245.598 | 147.017 | 151.795 |
| Krátkodobé investície | 184.729 | 148.092 | 149.71 | 98.913 | 148.139 | 214.458 |
| Pohľadávky celkom, netto | 2.769 | 0 | 3.669 | 5.206 | 6.433 | 4.945 |
| Prepaid Expenses | 1.72 | 1.848 | 4.255 | 5.531 | 6.837 | 8.082 |
| Total Assets | 276.994 | 248.941 | 246.085 | 380.403 | 329.043 | 402.387 |
| Property/Plant/Equipment, Total - Net | 27.194 | 24.873 | 23.893 | 19.475 | 14.526 | 14.116 |
| Property/Plant/Equipment, Total - Gross | 36.046 | 40.053 | 46.093 | 49.231 | 50.837 | 53.084 |
| Accumulated Depreciation, Total | -8.852 | -15.18 | -22.2 | -29.756 | -36.311 | -38.968 |
| Long Term Investments | 12.709 | 45.15 | 0 | |||
| Other Long Term Assets, Total | 2.41 | 3.385 | 7.635 | 5.68 | 6.091 | 8.991 |
| Total Current Liabilities | 37.693 | 36.893 | 41.486 | 39.718 | 42.583 | 61.355 |
| Accounts Payable | 8.424 | 1.892 | 5.775 | 9.026 | 9.663 | 5.246 |
| Accrued Expenses | 8.934 | 11.686 | 14.003 | 22.991 | 29.945 | 38.335 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 20.335 | 23.315 | 21.708 | 7.701 | 2.975 | 17.774 |
| Total Liabilities | 97.182 | 75.045 | 59.406 | 49.684 | 49 | 66.74 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 59.489 | 38.152 | 17.92 | 9.966 | 6.417 | 5.385 |
| Total Equity | 179.812 | 173.896 | 186.679 | 330.719 | 280.043 | 335.647 |
| Preferred Stock - Non Redeemable, Net | 294.874 | 294.874 | 294.874 | 0 | 0 | |
| Common Stock | 0.011 | 0.012 | 0.007 | 0.067 | 0.071 | 0.078 |
| Additional Paid-In Capital | 17.57 | 26.141 | 39.258 | 526.771 | 578.599 | 754.664 |
| Retained Earnings (Accumulated Deficit) | -132.541 | -146.7 | -147.193 | -196.144 | -298.631 | -418.966 |
| Other Equity, Total | -0.102 | -0.431 | -0.267 | 0.025 | 0.004 | -0.129 |
| Total Liabilities & Shareholders’ Equity | 276.994 | 248.941 | 246.085 | 380.403 | 329.043 | 402.387 |
| Total Common Shares Outstanding | 64.9937 | 64.9937 | 64.9937 | 66.9603 | 70.5854 | 77.9627 |
| Total Preferred Shares Outstanding | 0 | 0 | ||||
| Accounts Receivable - Trade, Net | 0 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Celkové aktíva | 425.849 | 403.129 | 395.883 | 379.28 | 337.622 |
| Hotovosť a krátkodobé investície | 412.656 | 390.55 | 383.429 | 366.253 | 329.832 |
| Hotovosť a ekvivalenty | 148.113 | 99.403 | 145.826 | 151.795 | 109.872 |
| Krátkodobé investície | 264.543 | 291.147 | 237.603 | 214.458 | 219.96 |
| Pohľadávky celkom, netto | 4.925 | 3.586 | 4.4 | 4.945 | 0.103 |
| Prepaid Expenses | 8.268 | 8.993 | 8.054 | 8.082 | 7.687 |
| Total Assets | 445.541 | 423.011 | 415.858 | 402.387 | 359.773 |
| Property/Plant/Equipment, Total - Net | 13.733 | 12.79 | 11.452 | 14.116 | 13.006 |
| Property/Plant/Equipment, Total - Gross | 51.257 | 50.027 | 50.195 | 53.084 | 53.329 |
| Accumulated Depreciation, Total | -37.524 | -37.237 | -38.743 | -38.968 | -40.323 |
| Other Long Term Assets, Total | 5.959 | 7.092 | 8.523 | 8.991 | 9.145 |
| Total Current Liabilities | 40.309 | 45.043 | 57.728 | 61.355 | 44.563 |
| Accounts Payable | 7.535 | 5.141 | 7.632 | 5.246 | 4.815 |
| Accrued Expenses | 29.763 | 31.891 | 34.72 | 38.335 | 34.631 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 3.011 | 8.011 | 15.376 | 17.774 | 5.117 |
| Total Liabilities | 45.964 | 49.936 | 61.819 | 66.74 | 48.636 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 5.655 | 4.893 | 4.091 | 5.385 | 4.073 |
| Total Equity | 399.577 | 373.075 | 354.039 | 335.647 | 311.137 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.077 | 0.077 | 0.078 | 0.078 | 0.078 |
| Additional Paid-In Capital | 725.693 | 735.86 | 745.704 | 754.664 | 763.152 |
| Retained Earnings (Accumulated Deficit) | -326.175 | -362.867 | -391.732 | -418.966 | -451.416 |
| Other Equity, Total | -0.018 | 0.005 | -0.011 | -0.129 | -0.677 |
| Total Liabilities & Shareholders’ Equity | 445.541 | 423.011 | 415.858 | 402.387 | 359.773 |
| Total Common Shares Outstanding | 76.9136 | 77.3072 | 77.6426 | 77.9627 | 78.087 |
| Total Preferred Shares Outstanding | 0 |
- Výročný
- Štvrťročne
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Čistý príjem/Počiatočná čiara | -6.922 | -14.159 | -0.493 | -42.795 | -102.487 | -120.335 |
| Hotovosť z prevádzkovej činnosti | 1.269 | -17.413 | -7.597 | -41.174 | -83.496 | -73.229 |
| Hotovosť z prevádzkovej činnosti | 3.534 | 6.441 | 7.223 | 7.605 | 6.555 | 6.089 |
| Bezhotovostné položky | 7.169 | 8.043 | 9.254 | 11.956 | 16.136 | 36.809 |
| Zmeny pracovného kapitálu | -2.512 | -17.738 | -23.581 | -17.94 | -3.7 | 4.208 |
| Peniaze z investičných činností | -64.707 | -2.796 | 38.729 | 48.723 | -50.998 | -71.65 |
| Kapitálové výdavky | -24.804 | -6.422 | -5.844 | -3.489 | -1.879 | -1.684 |
| Ostatné investičné položky peňažných tokov, celkom | -39.903 | 3.626 | 44.573 | 52.212 | -49.119 | -69.966 |
| Hotovosť z finančných činností | 0.231 | 0.339 | 0.198 | 180.751 | 35.538 | 149.657 |
| Vydanie (vyradenie) zásob, netto | 0.231 | 0.339 | 2.398 | 180.751 | 36.151 | 149.657 |
| Čistá zmena v hotovosti | -63.207 | -19.87 | 31.33 | 188.3 | -98.956 | 4.778 |
| Financovanie položiek peňažných tokov | -2.2 | -0.613 | 0 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -27.544 | -64.236 | -93.101 | -120.335 | -32.45 |
| Cash From Operating Activities | -22.225 | -45.535 | -54.894 | -73.229 | -35.738 |
| Cash From Operating Activities | 1.554 | 3.118 | 4.61 | 6.089 | 1.427 |
| Non-Cash Items | 6.837 | 19.465 | 26.838 | 36.809 | 9.273 |
| Changes in Working Capital | -3.072 | -3.882 | 6.759 | 4.208 | -13.988 |
| Cash From Investing Activities | -117.156 | -145.88 | -93.576 | -71.65 | -6.853 |
| Capital Expenditures | -0.16 | -1.355 | -1.551 | -1.684 | -0.285 |
| Other Investing Cash Flow Items, Total | -116.996 | -144.525 | -92.025 | -69.966 | -6.568 |
| Cash From Financing Activities | 140.477 | 143.801 | 147.279 | 149.657 | 0.668 |
| Issuance (Retirement) of Stock, Net | 140.477 | 143.801 | 147.279 | 149.657 | 0.668 |
| Net Change in Cash | 1.096 | -47.614 | -1.191 | 4.778 | -41.923 |
| Financing Cash Flow Items | 0 | 0 | 0 |
| Meno investora | Typ investora | Percento vynikajúce | Držané akcie | Zmena akcií | Dátum držby | Hodnotenie obratu |
|---|---|---|---|---|---|---|
| The Column Group LP | Venture Capital | 26.5053 | 21661782 | 546759 | 2023-01-31 | LOW |
| Merck Sharp & Dohme Corporation | Corporation | 15.8517 | 12955016 | 0 | 2022-03-10 | |
| EcoR1 Capital, LLC | Hedge Fund | 7.8745 | 6435518 | 5894410 | 2022-10-18 | MED |
| Fidelity Management & Research Company LLC | Investment Advisor | 5.1229 | 4186777 | 2126738 | 2022-09-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.7647 | 3894038 | 496089 | 2022-09-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.7429 | 3058965 | 71412 | 2022-09-30 | LOW |
| Rieflin (William J L) | Individual Investor | 3.3947 | 2774340 | 1805 | 2022-03-10 | LOW |
| Avidity Partners Management LP | Hedge Fund | 2.2002 | 1798100 | 1798100 | 2022-09-30 | MED |
| StepStone Group LP | Private Equity | 1.9252 | 1573357 | 0 | 2022-09-30 | LOW |
| Chen (Jin-Long) | Individual Investor | 1.3874 | 1133893 | 0 | 2023-01-17 | LOW |
| First Light Asset Management, LLC | Investment Advisor/Hedge Fund | 1.1692 | 955505 | -180379 | 2022-09-30 | LOW |
| Rubric Capital Management LP | Hedge Fund | 1.0733 | 877161 | 79573 | 2022-09-30 | MED |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.0469 | 855575 | 85133 | 2022-09-30 | LOW |
| Logos Global Management LLC | Investment Advisor | 1.0401 | 850000 | 850000 | 2022-09-30 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.964 | 787808 | 141090 | 2022-09-30 | LOW |
| Euclidean Capital, L.L.C. | Investment Advisor | 0.9136 | 746674 | 0 | 2022-09-30 | LOW |
| Nuveen LLC | Pension Fund | 0.904 | 738810 | 203372 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.9022 | 737316 | 8702 | 2022-09-30 | LOW |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.8253 | 674468 | 83987 | 2022-09-30 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 0.6689 | 546640 | 180720 | 2022-09-30 | HIGH |
Prečo si vybrať Capital.com? Naše čísla hovoria samy za seba.
Capital.com Group +500000+
Obchodníci
93000+
Aktívni klienti za mesia
$57000000+
Mesačný objem investícií
$31000000+
Vyskúšajte teraz Výbery každý mesiac
Obchodná kalkulačka
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Obchodná provízia
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Leverage (pákový efekt)
20:1
- 20
- 100
- 500
- 1000
- 10000
Investície
Veľkosť obchodu (pákový efekt x investície):
Otvorenie
Zatvorenie
Krátke Dlhé
NGM Biopharmaceuticals, Inc. Company profile
O spoločnosti NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc. je biofarmaceutická spoločnosť. Spoločnosť sa zameriava na objavovanie a vývoj nových liečiv založených na vedeckom poznaní kľúčových biologických dráh, ktoré sú základom ochorení pečene a metabolizmu, ochorení sietnice a rakoviny. Medzi kandidátske produkty spoločnosti patria aldafermín, MK-3655, NGM621, NGM120, NGM707 a NGM438. Aldafermín je upravený variant ľudského hormónu FGF19, ktorý spoločnosť vyvíja na liečbu nealkoholovej steatohepatitídy (NASH). MK-3655 je agonistická protilátka viažuca sa na receptor fibroblastového rastového faktora 1c-beta-klotho alebo FGFR1c/KLB a má potenciál ako inzulínový senzibilizátor na liečbu NASH. Vyvíja tiež NGM831, novú antagonistickú protilátku navrhnutú na blokovanie interakcie ILT3 fibronektínu, ako aj s inými ligandmi.
| Industry: | Bio Therapeutic Drugs |
333 Oyster Point Blvd
SOUTH SAN FRANCISCO
CALIFORNIA 94080-1978
US
Výkaz ziskov a strát
- Annual
- Quarterly
Ľudia tiež sledujú
Stále hľadáte brokera, ktorému sa dá veriť?
Pridajte sa k 500 000 obchodníkom na celom svete, ktorí sa rozhodli obchodovať s Capital.com